Skip to main content
logo
  • Healthcare professional
  • LFB Group
Logo Equilibrium
X
  • Home
  • About EquilYbrium
    • Our Mission
    • Steering Committee members
  • Immunodeficiencies
    • Primary Immunodeficiencies
      • ADVANCED CARE IN PID: From birth to adulthood: LFB Symposium IPIC 2015
      • THE IMMUNOLOGIST CONSULTATION; Recognizing the signs of X-linked agammaglobulinemia
      • NEW INSIGHTS IN THE USE OF INTRAVENOUS IMMUNOGLOBULINS: How to enhance PID patients clinical outcomes ?
    • Secondary Immunodeficiencies
      • SID IN A HEART TRANSPLANT PATIENT
  • Immunomodulation
    • Guillain-Barré Syndrome (GBS)
      • Guillain Barré Syndrome : From diagnosis to treatment
    • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
    • Multifocal Motor neuropathy (MMN)
  • Other therapeutic uses
    • Inflammatory Myopathies

Healthcare professionals

You can connect using your Onekey Web authentication account to access to the contents reserved for you.

By using the link below, you quit temporarly the LFB portal.

Sign in via OWA
My space
  • Home
  • About EquilYbrium
    • Our Mission
    • Steering Committee members
  • Immunodeficiencies
    • Primary Immunodeficiencies
      • ADVANCED CARE IN PID: From birth to adulthood: LFB Symposium IPIC 2015
      • THE IMMUNOLOGIST CONSULTATION; Recognizing the signs of X-linked agammaglobulinemia
      • NEW INSIGHTS IN THE USE OF INTRAVENOUS IMMUNOGLOBULINS: How to enhance PID patients clinical outcomes ?
    • Secondary Immunodeficiencies
      • SID IN A HEART TRANSPLANT PATIENT
  • Immunomodulation
    • Guillain-Barré Syndrome (GBS)
      • Guillain Barré Syndrome : From diagnosis to treatment
    • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
    • Multifocal Motor neuropathy (MMN)
  • Other therapeutic uses
    • Inflammatory Myopathies
  • LFB Group

Public site

  • Home
  • About EquilYbrium
  • Immunodeficiencies
  • Immunomodulation
  • Other Therapeutic Uses
  • Contact
  • Sitemap
  • CGU
  • D-19-0180

This activity is funded by LFB.
D-19-0180

The use of IVIG in these indications are under the responsibility of the physician.

I accept ▸